Printer Friendly

Phytopharm gets EU orphan drug status for Cogane for ALS.

M2 PHARMA-September 29, 2011-Phytopharm gets EU orphan drug status for Cogane for ALS(C)2011 M2 COMMUNICATIONS

29 September 2011 - US pharmaceutical company Phytopharm plc (LON:PYM) announced today that its lead development candidate Cogane, for the treatment of amyotrophic lateral sclerosis (ALS), had been granted Orphan Drug status by the European Commission.

Cogane received an Orphan Drug status from the United States Food and Drug Administration (US FDA) in July 2011. It has completed Phase I studies proving a good bioavailability and safety when administered orally once a day. The drug is currently in a Phase II trial of early stage Parkinson's disease as well as in preclinical models of ALS.

A study of Cogane in the genetic "gold standard" in vivo model of ALS is under way, supported by a grant from the UK Motor Neurone Disease Association. Results are expected by the end of 2011.

ALS, also known as Lou Gehrig's disease is a motor neurone disease, characterised by progressive loss of both lower (spinal cord and brain stem) and upper (cerebral cortex) motor neurones, which leads to severe muscle weakness and wasting, followed by paralysis and death. It affects people between 40 and 60 years of age, with a prevalence of 0.5--1.1 per 10,000 people in Europe.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 29, 2011
Words:225
Previous Article:EnteroMedics closes public offering of stock and warrants.
Next Article:Merck sells 50% stake in joint venture with Johnson & Johnson.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters